Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia

ConditionPost Herpetic Neuralgia (PHN)

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age35-65

SponsorMohamed Hosny Ismail Easa

About this trial

The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

pregnancy;

active implants (e.g., pacemakers, cochlear implants) or brain shunts;

previous neurological or psychiatric diagnoses;

history of addiction or substance abuse;

Trial design

Design model

Parallel

Treatments tested in this trial

transcutaneous auricular vagus nerve stimulation (taVNS)
Device
Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards
traditional medical treatment for PHN
Other intervention
Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.

Treatment groups

34 Participants

are divided into 2 treatment groups

Group A: Group (A): Study groupExperimental treatment 1 intervention

Group B: Group (B): Control groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

Brief Pain Inventory - Short Form (BPI-SF)

the Brief Pain Inventory-Short Form (BPI SF) is a valuable tool for assessing pain severity and its impact on daily functioning on a 0-10 numeric rating scale, with higher scores indicating more severe pain.

Time frame

Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.

Secondary outcomes

Short form McGill pain questionnaire 2 (SF-MPQ-2)

The SF-MPQ-2 is a validated tool assessing sensory, affective, and evaluative qualities of pain. Participants rate the intensity of their pain using a 0-10 scale: 0: No pain 10: Worst pain imaginable Participants select the rating that best reflects their experience during the past week.

Time frame

Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.

Locations

Map coordinates are unavailable for these locations. Locations are shown below instead.

Faculty of Physical Therapy - Cairo UniversityRecruiting12613, Cairo, Giza Governorate Egypt

Egypt

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mohamed Hosny Ismail Easa

Lead sponsor

Cairo University

Sponsor institution

Source ClinicalTrials.gov

Apply now